Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 1,736 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Administration first Clear all

Conditions: Acquired Thrombotic Thrombocytopenic Purpura
Interventions: Caplacizumab, Placebo; Biological
Lead sponsor: Ablynx, a Sanofi company; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 19
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 15 more

Conditions: Metastatic Pancreatic Adenocarcinoma
Interventions: Ibrutinib, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 28
States / cities: Huntsville, Alabama • Avondale, Arizona • Daly City, California + 24 more

Conditions: Anaemia
Interventions: GSK1278863, Placebo, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Azusa, California • Los Angeles, California • San Dimas, California + 13 more

Conditions: Hyperhidrosis
Interventions: Aluminum Chloride 20% (deodorant), Alcohol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Salt Lake City, Utah

Conditions: Type 2 Diabetes
Interventions: Biophoton Generators; Device
Lead sponsor: First Institute of All Medicines; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Tampa, Florida • Butler, Pennsylvania

Conditions: Obsessive-Compulsive Disorder
Interventions: Regular Titration, Placebo, Slow Titration; Drug
Lead sponsor: University of Florida; Other
Eligibility: 7 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Gainesville, Florida • Tampa, Florida

Conditions: Pain
Interventions: 4975, Placebo; Drug
Lead sponsor: Anesiva, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Bakersfield, California • Owings Mills, Maryland • Austin, Texas + 3 more

Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventions: Fuzuloparib , Abiraterone acetate and Prednisone, Fuzuloparib Placebo， Abiraterone acetate and Prednisone; Drug
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 17
States / cities: Anchorage, Alaska • Tucson, Arizona • Rancho Mirage, California + 13 more

Conditions: Crohn's Disease, Inflammatory Bowel Diseases
Interventions: Fluconazole, Placebo, IL-23 Therapy; Drug · Biological
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Calcium Phosphate Kidney Stones
Interventions: Placebo, Citric Acid, Potassium Citrate; Dietary Supplement
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hypoglycemia, Healthy
Interventions: Spironolactone, Placebo, Hypoglycemic Hyperinsulinemic Clamp, Euglycemic Hyperinsulinemic Clamp; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2025
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Arthritis, Rheumatoid
Interventions: LY3009104, Placebo, Methotrexate; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 31
States / cities: Paradise Valley, Arizona • Peoria, Arizona • Covina, California + 28 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: semaglutide, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 50 Years and older
Enrollment: 3,297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 97
States / cities: Birmingham, Alabama • Chandler, Arizona • Anaheim, California + 84 more

Conditions: Kidney Transplant
Interventions: ramipril; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 24
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Glimepiride, Placebo, Linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 16
States / cities: Chula Vista, California • Pembroke Pines, Florida • Decatur, Georgia + 11 more

Conditions: Palmoplantar Pustulosis
Interventions: Bimekizumab, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 8
States / cities: Birmingham, Alabama • Fremont, California • Miami, Florida + 5 more

Conditions: Pain Management, Peripheral Neuropathic Pain
Interventions: Cold Pressor Task - Upper Limb, Algometry Pain Tests in the Upper Limb, Algometry Pain Tests in the Lower Limb; Device
Lead sponsor: Evan (Huiliang) Wang; Other
Eligibility: 20 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Down Syndrome, Subclinical Hypothyroidism
Interventions: Levothyroxine; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 8 Years to 20 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Peanut Allergy
Interventions: walnut powder; Drug
Lead sponsor: Jonathan Spergel; Other
Eligibility: 6 Years to 21 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depression, Mild Cognitive Impairment
Interventions: Donepezil, Placebo, Citalopram, Venlafaxine; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 55 Years to 95 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: New York, New York • Durham, North Carolina

Conditions: Obsessive-Compulsive Disorder
Interventions: Ketamine, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Colitis Ulcerative
Interventions: Dupilumab, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 27
States / cities: Apple Valley, California • Beverly Hills, California • Oxnard, California + 24 more

Conditions: Blood Pressure, Hypertension
Interventions: Dextrose 20 % in 500 ML Injection, Intralipid, Saline, Ascorbic acid; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 79 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Search by objective public record fields.

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Hyperhidrosis, Developing a Treatment Approach Aims 1 & 2

RCT to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes

Effectiveness of Sertraline and Cognitive Behavioral Therapy in Treating Pediatric Obsessive-Compulsive Disorder

Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease

Treatment for Calcium Phosphate Kidney Stone Disease

Hypoglycemia and Autonomic Nervous System Function-B

A Study in Participants With Rheumatoid Arthritis on Background Methotrexate Therapy

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

Study Evaluating The Effect Of Ramipril On Urinary Protein Excretion In Renal Transplant Patients Converted To Sirolimus

Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Wearable Focused Ultrasound Stimulation for Peripheral Nerve Pain Management

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Treatment Trial of Subclinical Hypothyroidism in Down Syndrome

Walnut Oral Immunotherapy for Tree Nut Allergy

Combination Treatment Study for Memory Impairment and Depression

A Trial of Intranasal Ketamine for the Treatment of Obsessive-Compulsive Disorder

A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))

Reversing Glucose and Lipid-mediated Vascular Dysfunction